Methylene Blue 50 mg

Methylene Blue 50 mg is an oral tablet containing Methylthioninium Chloride. The FDA-approved injectable form of methylene blue is indicated for acquired methemoglobinemia. Non-medical uses referenced in community discussions include cognitive enhancement and mitochondrial support, but these fall outside approved indications.

The FDA-approved injectable dosing for methemoglobinemia is 1 mg/kg administered intravenously, with a possible repeat dose after one hour. No FDA-approved oral dosing exists for this product. Non-medical reports reference oral doses of 7.5–15 mg, which are substantially lower than the 50 mg tablet strength.

Methylene blue is not an anabolic steroid and does not suppress endogenous testosterone production. Post-cycle therapy designed for steroid cycles is not applicable. Its mechanism involves mitochondrial redox activity and MAO inhibition, which are unrelated to hormonal pathways.

Methylene blue acts as an electron carrier in the mitochondrial electron transport chain, potentially enhancing cellular respiration. It also inhibits nitric oxide synthase and guanylate cyclase, and functions as a monoamine oxidase inhibitor. These mechanisms underlie its medical use for methemoglobinemia and its investigational applications in other conditions.

In medical use for methemoglobinemia, the FDA label describes assessing response based on methemoglobin reduction within one hour after intravenous administration. Onset for other effects would depend on route of administration and individual factors. Non-medical reports describe subjective effects within 20–30 minutes of oral dosing, but these are anecdotal.

There is no universally best nootropic, and methylene blue is not established as a cognitive enhancer through rigorous clinical trials in healthy individuals. Its proposed cognitive effects are based on mechanistic reasoning and anecdotal reports rather than controlled studies. The compound carries significant pharmacological activity and potential for serious drug interactions.

Unlike most nootropics that modulate neurotransmitter receptors or reuptake, methylene blue operates through mitochondrial electron cycling and MAO inhibition. This fundamentally different mechanism means it does not fit conventional nootropic categories. Its MAO inhibition also creates interaction risks that most nootropics do not share.

50 mg is significantly higher than oral doses typically referenced in non-medical discussions, which commonly range from 7.5–15 mg. For the FDA-approved injectable indication, 1 mg/kg for an 80 kg individual would be 80 mg, but this is administered intravenously with clinical monitoring. The oral route and higher tablet strength of this product warrant particular caution.

Methylene Blue 50 mg by Dragon Pharma contains 50 mg of Methylthioninium Chloride per tablet. It is supplied as 100 oral tablets per package. A laboratory report dated March 23, 2026 measured the content at 53.72 mg, which is 107.44% of the label claim.

Yes. A published laboratory report dated March 23, 2026 measured Methylene Blue 50 mg at 53.72 mg, equivalent to 107.44% of its 50 mg label claim. The complete report can be viewed in the Lab Reports tab.

Methylene blue interacts dangerously with serotonergic drugs including SSRIs, SNRIs, and MAOIs, with risk of serotonin syndrome that can be fatal. It also inhibits multiple CYP450 enzymes and may affect metabolism of other drugs. Patients taking any medications should consult a healthcare provider before using methylene blue.